CA2620018A1 - Combinaisons stables de besylate d'amlodipine et d'hydrochlorure de benazepril - Google Patents

Combinaisons stables de besylate d'amlodipine et d'hydrochlorure de benazepril Download PDF

Info

Publication number: CA2620018A1
Authority: CA; Canada
Prior art keywords: amlodipine; composition; benazepril; crospovidone; microcrystalline cellulose
Prior art date: 2005-09-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002620018A

Other languages

English (en)

Inventor

Mali Kadosh

Fanny Leska

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Pharmaceutical Industries Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-28

Filing date

2005-09-28

Publication date

2007-04-12

2005-09-28 Application filed by Individual filed Critical Individual

2007-04-12 Publication of CA2620018A1 publication Critical patent/CA2620018A1/fr

Status Abandoned legal-status Critical Current

Links

SJSNKICFTZWKLT-KEHAGZLWSA-N benzenesulfonic acid;2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 SJSNKICFTZWKLT-KEHAGZLWSA-N 0.000 title description 2
229960000528 amlodipine Drugs 0.000 claims abstract description 50
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims abstract description 43
229960004530 benazepril Drugs 0.000 claims abstract description 41
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
238000000034 method Methods 0.000 claims abstract description 26
239000000203 mixture Substances 0.000 claims description 75
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 40
239000000546 pharmaceutical excipient Substances 0.000 claims description 37
239000008187 granular material Substances 0.000 claims description 36
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 34
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 31
229960000913 crospovidone Drugs 0.000 claims description 26
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 26
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 26
229960004005 amlodipine besylate Drugs 0.000 claims description 25
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 24
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 24
239000008108 microcrystalline cellulose Substances 0.000 claims description 24
229940016286 microcrystalline cellulose Drugs 0.000 claims description 24
229960003619 benazepril hydrochloride Drugs 0.000 claims description 23
VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims description 23
229940124531 pharmaceutical excipient Drugs 0.000 claims description 22
235000019359 magnesium stearate Nutrition 0.000 claims description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
238000005469 granulation Methods 0.000 claims description 14
230000003179 granulation Effects 0.000 claims description 14
229920000881 Modified starch Polymers 0.000 claims description 13
229920002472 Starch Polymers 0.000 claims description 13
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 13
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
238000007873 sieving Methods 0.000 claims description 13
229940032147 starch Drugs 0.000 claims description 13
239000008107 starch Substances 0.000 claims description 13
235000019698 starch Nutrition 0.000 claims description 13
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 12
229940078495 calcium phosphate dibasic Drugs 0.000 claims description 12
229920003109 sodium starch glycolate Polymers 0.000 claims description 12
229940079832 sodium starch glycolate Drugs 0.000 claims description 12
239000008109 sodium starch glycolate Substances 0.000 claims description 12
229940069328 povidone Drugs 0.000 claims description 11
238000005550 wet granulation Methods 0.000 claims description 11
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 10
229960001021 lactose monohydrate Drugs 0.000 claims description 10
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
229920000053 polysorbate 80 Polymers 0.000 claims description 10
229940068968 polysorbate 80 Drugs 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 5
238000003801 milling Methods 0.000 claims description 5
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
229940071117 starch glycolate Drugs 0.000 claims 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract description 45
239000002775 capsule Substances 0.000 description 17
239000004480 active ingredient Substances 0.000 description 9
239000002552 dosage form Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
-1 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-methyl-3,5-pyridinedicarboxylate benzenesulphonate Chemical compound 0.000 description 6
239000007857 degradation product Substances 0.000 description 6
239000012535 impurity Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000005541 ACE inhibitor Substances 0.000 description 4
229940127291 Calcium channel antagonist Drugs 0.000 description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
239000000480 calcium channel blocker Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000012453 solvate Substances 0.000 description 4
AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
SRTZYSFUFGOMFR-FKLPMGAJSA-N 2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 SRTZYSFUFGOMFR-FKLPMGAJSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940080288 lotrel Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940033134 talc Drugs 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
229940042746 amlodipine / benazepril Drugs 0.000 description 1
229960004067 benazeprilat Drugs 0.000 description 1
MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000012458 free base Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229960000540 polacrilin potassium Drugs 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002620018A 2005-09-28 2005-09-28 Combinaisons stables de besylate d'amlodipine et d'hydrochlorure de benazepril Abandoned CA2620018A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2005/034930 WO2007040511A1 (fr)	2005-09-28	2005-09-28	Combinaisons stables de bésylate d'amlodipine et d'hydrochlorure de bénazépril

Publications (1)

Publication Number	Publication Date
CA2620018A1 true CA2620018A1 (fr)	2007-04-12

Family

ID=35501279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002620018A Abandoned CA2620018A1 (fr)	2005-09-28	2005-09-28	Combinaisons stables de besylate d'amlodipine et d'hydrochlorure de benazepril

Country Status (5)

Country	Link
JP (1)	JP2009508948A (fr)
AU (1)	AU2005336956A1 (fr)
CA (1)	CA2620018A1 (fr)
IL (1)	IL189613A0 (fr)
WO (1)	WO2007040511A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10130624B2 (en)	2005-03-15	2018-11-20	Lupin Limited	Pharmaceutical compositions of amlodipine and benazepril
WO2008065485A2 (fr) *	2006-10-19	2008-06-05	Torrent Pharmaceuticals Limited	Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace
KR20120130761A (ko) *	2010-02-24	2012-12-03	사노피-아벤티스 도이칠란트 게엠베하	라미프릴 및 암로디핀 베실레이트의 고형 약제학적 제형, 및 이의 제조
CN102440993B (zh) *	2011-12-08	2013-04-17	扬子江药业集团广州海瑞药业有限公司	一种氨氯地平和贝那普利的药物组合物
PL227900B1 (pl)	2012-11-15	2018-01-31	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
AU2581601A (en) *	2000-12-18	2002-07-01	Novartis Ag	Therapeutic combination of amlodipine and benazepril
AT5874U1 (de) *	2000-12-29	2003-01-27	Bioorg Bv	Pharmazeutische zubereitungen enthaltend amlodipinmaleat

2005
- 2005-09-28 CA CA002620018A patent/CA2620018A1/fr not_active Abandoned
- 2005-09-28 WO PCT/US2005/034930 patent/WO2007040511A1/fr active Application Filing
- 2005-09-28 JP JP2008532202A patent/JP2009508948A/ja active Pending
- 2005-09-28 AU AU2005336956A patent/AU2005336956A1/en not_active Abandoned
2008
- 2008-02-19 IL IL189613A patent/IL189613A0/en unknown

Also Published As

Publication number	Publication date
JP2009508948A (ja)	2009-03-05
IL189613A0 (en)	2008-08-07
AU2005336956A1 (en)	2007-04-12
WO2007040511A1 (fr)	2007-04-12

Legal Events

Date	Code	Title	Description
2008-02-21	EEER	Examination request
2011-09-28	FZDE	Discontinued

Publication	Publication Date	Title
US8158146B2 (en)	2012-04-17	Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1814527B1 (fr)	2013-12-18	Comprime bicouche contenant du telmisartan et de l'amlodipine
AU2009349125B2 (en)	2016-05-19	Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
MXPA03005883A (es)	2005-04-19	Composiciones farmaceuticas que comprenden maleato de amlodipina.
AU2001290354A1 (en)	2003-01-23	Pharmaceutical compositions comprising amlodipine maleate
CN1481241A (zh)	2004-03-10	阿洛地平和贝那普利/苯那普利拉的治疗组合
WO2010127205A2 (fr)	2010-11-04	Formulations de combinaison de médicament à dose fixe
US20120107397A1 (en)	2012-05-03	Pharmaceutical compositions of valsartan
JP2011507973A (ja)	2011-03-10	アムロジピンとバルサルタンとの医薬組成物
CA2620018A1 (fr)	2007-04-12	Combinaisons stables de besylate d'amlodipine et d'hydrochlorure de benazepril
KR101171375B1 (ko)	2012-08-13	난용성 약물을 함유하는 경구 제형
WO2012055941A1 (fr)	2012-05-03	Composition pharmaceutique multicouche comprenant du telmisartan et de l'amlodipine
WO2008065485A2 (fr)	2008-06-05	Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace
EP2067470A1 (fr)	2009-06-10	Compositions pharmaceutiques contenant du valsartan et procédé pour sa préparation
EP1797885B1 (fr)	2008-03-26	Combinations stables d'amlodipine besylate et de benazeprile hydrochloride
CN101272791A (zh)	2008-09-24	苯磺酸氨氯地平和盐酸贝那普利的稳定的组合
JP6363079B2 (ja)	2018-07-25	アトルバスタチン、イルベサルタンおよび炭酸マグネシウムを含有する二層複合錠製剤
US20110206761A1 (en)	2011-08-25	Stable dosage forms of antihypertensive agents
WO2013098578A1 (fr)	2013-07-04	Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
WO2013098576A1 (fr)	2013-07-04	Composition pharmaceutique de valsartan à libération immédiate
WO2024109927A1 (fr)	2024-05-30	Composition pharmaceutique comprenant du potassium d'azilsartan médoxomil et un bloqueur de canal calcique, son procédé de préparation et son utilisation
CN102038682A (zh)	2011-05-04	含有氨氯地平和阿托伐他汀钙溶剂化物的药物组合物
US20150374713A1 (en)	2015-12-31	Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
CA2785920A1 (fr)	2011-07-14	Forme posologique orale solide contenant de l'olmesartan medoxomil
CZ12025U1 (cs)	2002-03-04	Farmaceutické prostředky obsahující amlodipinmaleát a jejich použití